Logo image of ISRG

INTUITIVE SURGICAL INC (ISRG) Stock Fundamental Analysis

USA - NASDAQ:ISRG - US46120E6023 - Common Stock

434.84 USD
-0.77 (-0.18%)
Last: 10/16/2025, 3:46:53 PM
Fundamental Rating

7

ISRG gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. ISRG scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ISRG is growing strongly while it is still valued neutral. This is a good combination! These ratings would make ISRG suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year ISRG was profitable.
In the past year ISRG had a positive cash flow from operations.
In the past 5 years ISRG has always been profitable.
In the past 5 years ISRG always reported a positive cash flow from operatings.
ISRG Yearly Net Income VS EBIT VS OCF VS FCFISRG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

1.2 Ratios

The Return On Assets of ISRG (12.93%) is better than 94.76% of its industry peers.
Looking at the Return On Equity, with a value of 14.52%, ISRG belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 13.28%, ISRG belongs to the top of the industry, outperforming 93.19% of the companies in the same industry.
ISRG had an Average Return On Invested Capital over the past 3 years of 12.20%. This is above the industry average of 8.89%.
The last Return On Invested Capital (13.28%) for ISRG is above the 3 year average (12.20%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.93%
ROE 14.52%
ROIC 13.28%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ISRG Yearly ROA, ROE, ROICISRG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

Looking at the Profit Margin, with a value of 28.51%, ISRG belongs to the top of the industry, outperforming 95.81% of the companies in the same industry.
In the last couple of years the Profit Margin of ISRG has declined.
The Operating Margin of ISRG (28.93%) is better than 96.86% of its industry peers.
In the last couple of years the Operating Margin of ISRG has declined.
With a decent Gross Margin value of 66.61%, ISRG is doing good in the industry, outperforming 71.73% of the companies in the same industry.
In the last couple of years the Gross Margin of ISRG has remained more or less at the same level.
Industry RankSector Rank
OM 28.93%
PM (TTM) 28.51%
GM 66.61%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
ISRG Yearly Profit, Operating, Gross MarginsISRG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

ISRG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, ISRG has more shares outstanding
ISRG has more shares outstanding than it did 5 years ago.
ISRG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ISRG Yearly Shares OutstandingISRG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ISRG Yearly Total Debt VS Total AssetsISRG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

ISRG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.53
WACC8.67%
ISRG Yearly LT Debt VS Equity VS FCFISRG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

A Current Ratio of 5.64 indicates that ISRG has no problem at all paying its short term obligations.
ISRG has a Current ratio of 5.64. This is amongst the best in the industry. ISRG outperforms 81.68% of its industry peers.
ISRG has a Quick Ratio of 4.89. This indicates that ISRG is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 4.89, ISRG belongs to the best of the industry, outperforming 83.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 4.89
ISRG Yearly Current Assets VS Current LiabilitesISRG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.97% over the past year.
The Earnings Per Share has been growing by 11.48% on average over the past years. This is quite good.
The Revenue has grown by 20.77% in the past year. This is a very strong growth!
ISRG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.27% yearly.
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%

3.2 Future

ISRG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.53% yearly.
Based on estimates for the next years, ISRG will show a quite strong growth in Revenue. The Revenue will grow by 14.89% on average per year.
EPS Next Y13.54%
EPS Next 2Y13.54%
EPS Next 3Y14.49%
EPS Next 5Y14.53%
Revenue Next Year19.76%
Revenue Next 2Y17.08%
Revenue Next 3Y16.38%
Revenue Next 5Y14.89%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ISRG Yearly Revenue VS EstimatesISRG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
ISRG Yearly EPS VS EstimatesISRG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 54.02, the valuation of ISRG can be described as expensive.
67.54% of the companies in the same industry are more expensive than ISRG, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.53, ISRG is valued quite expensively.
With a Price/Forward Earnings ratio of 46.02, ISRG can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ISRG is valued a bit cheaper than 69.63% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ISRG to the average of the S&P500 Index (23.04), we can say ISRG is valued expensively.
Industry RankSector Rank
PE 54.02
Fwd PE 46.02
ISRG Price Earnings VS Forward Price EarningsISRG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

67.02% of the companies in the same industry are more expensive than ISRG, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ISRG is valued a bit cheaper than the industry average as 71.73% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 78.16
EV/EBITDA 45.52
ISRG Per share dataISRG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ISRG does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of ISRG may justify a higher PE ratio.
A more expensive valuation may be justified as ISRG's earnings are expected to grow with 14.49% in the coming years.
PEG (NY)3.99
PEG (5Y)4.7
EPS Next 2Y13.54%
EPS Next 3Y14.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ISRG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTUITIVE SURGICAL INC

NASDAQ:ISRG (10/16/2025, 3:46:53 PM)

434.84

-0.77 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-22 2025-07-22/amc
Earnings (Next)10-21 2025-10-21/amc
Inst Owners88.66%
Inst Owner Change-0.43%
Ins Owners0.45%
Ins Owner Change1.58%
Market Cap155.88B
Analysts79
Price Target597.45 (37.4%)
Short Float %1.6%
Short Ratio2.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.33%
Min EPS beat(2)3.05%
Max EPS beat(2)11.61%
EPS beat(4)4
Avg EPS beat(4)11.45%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.83%
EPS beat(12)11
Avg EPS beat(12)6.4%
EPS beat(16)13
Avg EPS beat(16)4.58%
Revenue beat(2)2
Avg Revenue beat(2)1.47%
Min Revenue beat(2)1.09%
Max Revenue beat(2)1.84%
Revenue beat(4)3
Avg Revenue beat(4)1.98%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)7
Avg Revenue beat(16)0.13%
PT rev (1m)0%
PT rev (3m)0.65%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)2.28%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)4.06%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.95%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)1.46%
Valuation
Industry RankSector Rank
PE 54.02
Fwd PE 46.02
P/S 17.05
P/FCF 78.16
P/OCF 55.16
P/B 8.68
P/tB 8.85
EV/EBITDA 45.52
EPS(TTM)8.05
EY1.85%
EPS(NY)9.45
Fwd EY2.17%
FCF(TTM)5.56
FCFY1.28%
OCF(TTM)7.88
OCFY1.81%
SpS25.51
BVpS50.08
TBVpS49.11
PEG (NY)3.99
PEG (5Y)4.7
Profitability
Industry RankSector Rank
ROA 12.93%
ROE 14.52%
ROCE 14.74%
ROIC 13.28%
ROICexc 28.31%
ROICexgc 29.53%
OM 28.93%
PM (TTM) 28.51%
GM 66.61%
FCFM 21.81%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ROICexc(3y)18.44%
ROICexc(5y)19.03%
ROICexgc(3y)19.29%
ROICexgc(5y)20.12%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexcg growth 3Y-7.59%
ROICexcg growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 144.66%
Cap/Sales 9.1%
Interest Coverage 250
Cash Conversion 87.74%
Profit Quality 76.48%
Current Ratio 5.64
Quick Ratio 4.89
Altman-Z N/A
F-Score6
WACC8.67%
ROIC/WACC1.53
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
EPS Next Y13.54%
EPS Next 2Y13.54%
EPS Next 3Y14.49%
EPS Next 5Y14.53%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
Revenue Next Year19.76%
Revenue Next 2Y17.08%
Revenue Next 3Y16.38%
Revenue Next 5Y14.89%
EBIT growth 1Y34.69%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year40.01%
EBIT Next 3Y23.66%
EBIT Next 5Y20.2%
FCF growth 1Y69.15%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y52.09%
OCF growth 3Y4.95%
OCF growth 5Y8.61%